Sanjiv Patel, Relay CEO

Re­lay un­rolls ear­ly da­ta for an­ti-FGFR drug it thinks stand alone in terms of safe­ty pro­file

When Third Rock-backed Re­lay Ther­a­peu­tics went pub­lic last year, it ar­gued its nov­el drug de­sign plat­form could po­ten­tial­ly break the code in a range of hard-to-treat tu­mor types. Now, the biotech’s proof-of-con­cept drug is read­ing out ear­ly da­ta — and they look com­pet­i­tive.

Re­lay’s FGFR2 in­hibitor RLY-4008 un­corked three con­firmed par­tial re­spons­es among six pa­tients with FGFR2 fu­sion-pos­i­tive cholan­gio­car­ci­no­ma, a form of bile duct can­cer, who had not been pre­vi­ous­ly treat­ed with what are known as “pan-FGFR” in­hibitors, ac­cord­ing to Phase I da­ta pre­sent­ed Fri­day at the vir­tu­al AACR-NCI-EORTC Mol­e­c­u­lar Tar­gets Con­fer­ence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.